Stephen Nimer, MD, Sylvester Comprehensive Cancer Center and University of Miami, Miami, FL, discusses the importance of developing targeted and epigenetic therapies that effectively eliminate myelodysplastic syndromes (MDS) clones. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.